Screener
Avalo Therapeutics AVTX Derivative Liability, Noncurrent
Derivative Liability, Noncurrent at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesNoncurrent.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total current liabilities | 21,130 | 12,940 |
| Royalty obligation | 2,000 | 2,000 |
| Deferred tax liability, net | 463 | 434 |
| Derivative liability, non-current | 18,530 | 18,000 |
| Other long-term liabilities | — | 35 |
| Total liabilities | 42,123 | 33,409 |
| Mezzanine equity: | ||
| Series D Preferred Stock—$0.001 par value; 0 and 1 share of Series D Preferred Stock authorized at June 30, 2026 and December 31, 2025, respectively; 0 and 1 share of Series D Preferred Stock issued and outstanding at June 30, 2026 and December 31, 2025, respectively | — | — |
Item 1. Financial Statements.
FAQ
- What is Avalo Therapeutics's derivative liability, noncurrent?
- Avalo Therapeutics (AVTX) reported derivative liability, noncurrent of $18.53M in Q2 2026.
- How has Avalo Therapeutics's derivative liability, noncurrent changed year-over-year?
- Avalo Therapeutics's derivative liability, noncurrent increased by 80.6% year-over-year, from $10.26M to $18.53M.
- What does derivative liability, noncurrent mean?
- Derivative Liability, Noncurrent
Ask your AI about Avalo Therapeutics's derivative liability, noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude